Key result
Beta-blockers provide cardioprotection in primary and secondary prevention, with evidence suggesting this effect is even greater in hypertensive diabetic patients despite their worse risk profile.
Why the study?
Do beta-blockers provide cardioprotection in hypertensive diabetic patients?
Do beta-blockers provide cardioprotection in hypertensive diabetic patients?
This review highlights the established cardioprotective role of beta-blockers in hypertensive diabetic patients, emphasizing their benefit despite the population's higher risk profile.
May support beta-blockers in hypertensive diabetes; leaves open need for prospective RCTs.
Clinical trials have not yet produced long-term primary prevention data on the effects of angiotensin converting enzyme inhibitors, calcium antagonists or alpha-blockers on cardiovascular complications and sudden death in hypertensive patients. Large-scale secondary preventive studies on calcium antagonists have been disappointing. In contrast, beta-blockers have an established role in cardioprotection both in primary and secondary preventive studies and there is evidence to show that the cardioprotective effect of beta-blockers is even greater in the diabetic population. Furthermore, this favourable impact of beta-blockers was achieved despite diabetic patients having a worse risk factor profile and poorer prognosis. In this review the use of beta-blockers in diabetic patients will be discussed and their impact on coronary artery disease described.
No takes yet. Share an insight, caveat, or question.
Tse et al. (1994) conducted a review in Hypertension and diabetes. Beta-blockers was evaluated. Beta-blockers provide cardioprotection in primary and secondary prevention, with evidence suggesting this effect is even greater in hypertensive diabetic patients despite their worse risk profile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: